Connective
tissue growth factor or CTGF is a revolutionary cysteine-rich, secreted
peptide, which is concerned in human atherosclerosis and fibrotic disorders for
instance systemic scleroderma. It is an adherent of the peptide family that
contains serum-induced immediate early gene products, a putative proto-oncogene
and a v-src–induced peptide. The CTGF gene family is a modular protein and is
preserved throughout evolution. CTGF mRNA has been found in the mouse, chicken,
human, frog, and fly. Key functions of the CTGF gene family include wound
healing, embryogenesis and regulation of extracellular matrix production. Human
connective tissue growth factor is undetectable in normal blood vessels but
overexpressed in atherosclerotic injuries.
Based
on product type, connective tissue growth factor market is segmented into BLR-200,
OLX-201, IB-DMD, PBI-4050 and others. Based on diagnosis, market is segmented
into X-ray examination, physical examination, ANA (Antinuclear Antibody Test),
and others. Based on treatment, market is segmented into non-steroidal
anti-inflammatory drugs (NSAIDs), antimalarial drugs, cortisone drugs or
steroids, cytotoxic drugs, and others. Based on application, market is
segmented into hypertrophic scars, genetic disorders, liver fibrosis,
opthalmology and others. In addition, based on end-user, market is segmented
into diagnostic clinics, hospital, and others.
The
connective tissue growth factor market is driven by increase in the research
& development (R&D) efforts to find treatment or cure for connective
tissue disease, followed by rise in prevalence of connective tissue disease
across the globe especially in women, increase in awareness & rise in
acceptance among the general population about connective tissue diseases,
growth in expenditure on healthcare and high unmet medical needs of the current
treatment. However, lack of funds in middle & low-income countries,
inadequate R&D infrastructure and lack of a knowledgeable workforce may
impact the market. Moreover, growth in support from governments across the
world along with rise in funds for R&D from the private industry is a key
opportunity for market.
Based
on geography, the North-American region holds major share in connective tissue
growth factor market owing to increase in healthcare expenditure and rise in
awareness among people about treatment of connective tissue disease in the
region. Whereas, the European region is anticipated to exhibit substantial
growth rate due to growth in improvement in reimbursement policies in
healthcare over the forecast period. The Asian-Pacific region is also anticipated
to exhibit substantial growth rate as a result of rise in developing healthcare
technology and huge patient pool over the forecast period. In near future, it
is expected that the market will be reached at rapid pace on account of rise in
diagnosed and drug-treated population during the forecast period.
For More Information,
click on the link below:-
Related Reports:-
Contact Us:-
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249